Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.53 |
| ▸ | RXRB | P28702 | 4/20 | 0.53 |
| ▸ | RXRG | P48443 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628795 | 0.92 | RXRA (0.49) | RXRARXRBRXRGLMNAPPARG | |
| SCHEMBL629104 | 0.86 | S1PR1 (0.43) | RXRARXRBRXRGLMNAPPARG | |
| SCHEMBL27767986 | 0.84 | PPARG (0.48) | RXRARXRBRXRGLMNAPPARG | |
| SCHEMBL629626 | 0.83 | RXRA (0.57) | RXRARXRBRXRGLMNAPPARG | |
| SCHEMBL10029574 | 0.82 | LMNA (0.46) | LMNAGAATSHRKMT2AFFAR1 | |
| SCHEMBL2108560 | 0.81 | PTPN11 (0.41) | RXRARXRBRXRGLMNAPPARG | |
| SCHEMBL2108233 | 0.80 | CTSK (0.40) | RXRARXRBRXRGLMNAPPARG | |
| SCHEMBL628808 | 0.79 | LMNA (0.41) | RXRARXRBRXRGLMNAPPARG | |
| SCHEMBL2108474 | 0.77 | PPARG (0.40) | RXRARXRBRXRGPPARGPPARA | |
| SCHEMBL2108513 | 0.77 | PPARG (0.46) | RXRARXRBRXRGLMNAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-03-29 | — | — | US | disclosed |
| EP-2419412-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120741-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | RBP4, RBP1, FABP4 | RXRA 11/4885RXRB 5/4885RXRG 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.